Biogen (BIIB) – Investment Analysts’ Recent Ratings Updates

Biogen (NASDAQ: BIIB) has recently received a number of price target changes and ratings updates:

  • 4/11/2018 – Biogen was given a new $433.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 4/10/2018 – Biogen was given a new $318.00 price target on by analysts at Sanford C. Bernstein. They now have a “buy” rating on the stock.
  • 4/9/2018 – Biogen was given a new $350.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
  • 4/5/2018 – Biogen was downgraded by analysts at Barclays from an “overweight” rating to an “equal weight” rating. They now have a $295.00 price target on the stock, down previously from $395.00.
  • 3/12/2018 – Biogen was given a new $433.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 3/12/2018 – Biogen had its “buy” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $384.00 price target on the stock.
  • 3/2/2018 – Biogen had its price target lowered by analysts at BMO Capital Markets from $403.00 to $393.00. They now have an “outperform” rating on the stock.
  • 3/2/2018 – Biogen was given a new $400.00 price target on by analysts at Guggenheim. They now have a “buy” rating on the stock.
  • 2/24/2018 – Biogen was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 2/22/2018 – Biogen was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating.
  • 2/16/2018 – Biogen was downgraded by analysts at Argus from a “buy” rating to a “hold” rating.

NASDAQ:BIIB opened at $263.11 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.34. Biogen has a one year low of $244.28 and a one year high of $370.57. The company has a market cap of $56,146.63, a P/E ratio of 12.06, a price-to-earnings-growth ratio of 1.46 and a beta of 0.86.

How to Become a New Pot Stock Millionaire

Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing the consensus estimate of $5.44 by ($0.18). Biogen had a return on equity of 38.32% and a net margin of 20.69%. The business had revenue of $3.31 billion for the quarter, compared to analyst estimates of $3.08 billion. During the same quarter in the prior year, the business earned $5.04 earnings per share. The firm’s quarterly revenue was up 15.1% on a year-over-year basis. analysts expect that Biogen will post 24.85 earnings per share for the current fiscal year.

In related news, EVP Alfred Sandrock sold 259 shares of Biogen stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $290.83, for a total transaction of $75,324.97. Following the sale, the executive vice president now directly owns 6,553 shares in the company, valued at approximately $1,905,808.99. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 2,296 shares of company stock worth $678,993. 0.25% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. ADAMCAPITAL Gestao de Recursos Ltda. bought a new position in Biogen during the 4th quarter worth approximately $29,896,000. Xact Kapitalforvaltning AB raised its holdings in Biogen by 9.1% during the 4th quarter. Xact Kapitalforvaltning AB now owns 44,104 shares of the biotechnology company’s stock worth $14,050,000 after purchasing an additional 3,684 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in Biogen by 3.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 59,911 shares of the biotechnology company’s stock worth $19,086,000 after purchasing an additional 2,246 shares during the last quarter. CNB Bank bought a new position in Biogen during the 4th quarter worth approximately $398,000. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its holdings in Biogen by 32.3% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 160,230 shares of the biotechnology company’s stock worth $51,044,000 after purchasing an additional 39,136 shares during the last quarter. Hedge funds and other institutional investors own 88.92% of the company’s stock.

Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply